Abstract
Interferon alpha (IFN-α) represents an adjuvant therapy of proven effectiveness in increasing disease-free interval and survival in subgroups of melanoma patients. Since high doses of cytokine are required, the treatment is often accompanied by toxic side effects. Furthermore, naturally occurring insensitivity to IFN-α may hamper its therapeutic efficacy. Clinical, molecular or immunological markers enabling the selection of potential responders have not been identified so far. To explore the molecular basis of IFN-α responsiveness, we analysed the expression pattern of about 7000 genes in IFN-α sensitive and resistant cell lines and we compared the transcription profiles of cells cultured in the presence or absence of the cytokine using high-density oligonucleotide arrays. Melanoma cell lines were screened for their sensitivity to proliferation inhibition and HLA class I induction upon IFN-α treatment by standard 3H-thymidine incorporation and flow-cytometry. The study of 4 sensitive and 2 resistant cell lines allowed the identification of 4 genes (RCC1, IFI16, hox2 and h19) preferentially transcribed in sensitive cells and 2 (SHB and PKC-ζ) preferentially expressed in resistant cells. IFN-α stimulation resulted in the expression of a panel of 19 known inducible genes in sensitive but not in resistant cells. Moreover a group of 30 novel IFN-α inducible genes was identified. These data may provide a useful basis to develop diagnostic tools to select potential IFN-α responders eligible for treatment, while avoiding unnecessary toxicity to non-responders. Furthermore, by extending the knowledge of the polymorphic effects of IFN-α on gene expression, they offer novel clues to the study of its pleiotropic toxicity. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: IFN-α sensitivity, melanoma, DNA microarrays, gene expression, pharmacogenomics
Full Text
The Full Text of this article is available as a PDF (227.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Acampora D., D'Esposito M., Faiella A., Pannese M., Migliaccio E., Morelli F., Stornaiuolo A., Nigro V., Simeone A., Boncinelli E. The human HOX gene family. Nucleic Acids Res. 1989 Dec 25;17(24):10385–10402. doi: 10.1093/nar/17.24.10385. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Adams F., Fernandez F., Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol. 1988 Dec;6(4):355–359. doi: 10.1007/BF00177432. [DOI] [PubMed] [Google Scholar]
- Aebi M., Fäh J., Hurt N., Samuel C. E., Thomis D., Bazzigher L., Pavlovic J., Haller O., Staeheli P. cDNA structures and regulation of two interferon-induced human Mx proteins. Mol Cell Biol. 1989 Nov;9(11):5062–5072. doi: 10.1128/mcb.9.11.5062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Agarwala S. S., Kirkwood J. M. Interferons in melanoma. Curr Opin Oncol. 1996 Mar;8(2):167–174. doi: 10.1097/00001622-199603000-00015. [DOI] [PubMed] [Google Scholar]
- Barbee J. L., Deutscher S. L., Loomis C. R., Burns D. J. The cDNA sequence encoding human protein kinase C-zeta. Gene. 1993 Oct 15;132(2):305–306. doi: 10.1016/0378-1119(93)90213-m. [DOI] [PubMed] [Google Scholar]
- Bischoff F. R., Ponstingl H. Catalysis of guanine nucleotide exchange on Ran by the mitotic regulator RCC1. Nature. 1991 Nov 7;354(6348):80–82. doi: 10.1038/354080a0. [DOI] [PubMed] [Google Scholar]
- Brannan C. I., Dees E. C., Ingram R. S., Tilghman S. M. The product of the H19 gene may function as an RNA. Mol Cell Biol. 1990 Jan;10(1):28–36. doi: 10.1128/mcb.10.1.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Crackower M. A., Scherer S. W., Rommens J. M., Hui C. C., Poorkaj P., Soder S., Cobben J. M., Hudgins L., Evans J. P., Tsui L. C. Characterization of the split hand/split foot malformation locus SHFM1 at 7q21.3-q22.1 and analysis of a candidate gene for its expression during limb development. Hum Mol Genet. 1996 May;5(5):571–579. doi: 10.1093/hmg/5.5.571. [DOI] [PubMed] [Google Scholar]
- Deblandre G. A., Marinx O. P., Evans S. S., Majjaj S., Leo O., Caput D., Huez G. A., Wathelet M. G. Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. J Biol Chem. 1995 Oct 6;270(40):23860–23866. doi: 10.1074/jbc.270.40.23860. [DOI] [PubMed] [Google Scholar]
- Der S. D., Zhou A., Williams B. R., Silverman R. H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15623–15628. doi: 10.1073/pnas.95.26.15623. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fambrough D., McClure K., Kazlauskas A., Lander E. S. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes. Cell. 1999 Jun 11;97(6):727–741. doi: 10.1016/s0092-8674(00)80785-0. [DOI] [PubMed] [Google Scholar]
- Grob J. J., Dreno B., de la Salmonière P., Delaunay M., Cupissol D., Guillot B., Souteyrand P., Sassolas B., Cesarini J. P., Lionnet S. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998 Jun 27;351(9120):1905–1910. doi: 10.1016/s0140-6736(97)12445-x. [DOI] [PubMed] [Google Scholar]
- Gurney M. E., Heinrich S. P., Lee M. R., Yin H. S. Molecular cloning and expression of neuroleukin, a neurotrophic factor for spinal and sensory neurons. Science. 1986 Oct 31;234(4776):566–574. doi: 10.1126/science.3764429. [DOI] [PubMed] [Google Scholar]
- Itoh S., Harada H., Fujita T., Mimura T., Taniguchi T. Sequence of a cDNA coding for human IRF-2. Nucleic Acids Res. 1989 Oct 25;17(20):8372–8372. doi: 10.1093/nar/17.20.8372. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Iyer V. R., Eisen M. B., Ross D. T., Schuler G., Moore T., Lee J. C., Trent J. M., Staudt L. M., Hudson J., Jr, Boguski M. S. The transcriptional program in the response of human fibroblasts to serum. Science. 1999 Jan 1;283(5398):83–87. doi: 10.1126/science.283.5398.83. [DOI] [PubMed] [Google Scholar]
- Keilholz U., Eggermont A. M. The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative Group. Oncology. 2000 Feb;58(2):89–95. doi: 10.1159/000012085. [DOI] [PubMed] [Google Scholar]
- Kirkwood J. M. Adjuvant IFN alpha2 therapy of melanoma. Lancet. 1998 Jun 27;351(9120):1901–1903. doi: 10.1016/S0140-6736(05)78608-6. [DOI] [PubMed] [Google Scholar]
- Lipshutz R. J., Fodor S. P., Gingeras T. R., Lockhart D. J. High density synthetic oligonucleotide arrays. Nat Genet. 1999 Jan;21(1 Suppl):20–24. doi: 10.1038/4447. [DOI] [PubMed] [Google Scholar]
- Lo Nigro C., Venesio T., Reymond A., Meroni G., Alberici P., Cainarca S., Enrico F., Stack M., Ledbetter D. H., Liscia D. S. The human ROX gene: genomic structure and mutation analysis in human breast tumors. Genomics. 1998 Apr 15;49(2):275–282. doi: 10.1006/geno.1998.5241. [DOI] [PubMed] [Google Scholar]
- Luster A. D., Weinshank R. L., Feinman R., Ravetch J. V. Molecular and biochemical characterization of a novel gamma-interferon-inducible protein. J Biol Chem. 1988 Aug 25;263(24):12036–12043. [PubMed] [Google Scholar]
- Lutfalla G., Holland S. J., Cinato E., Monneron D., Reboul J., Rogers N. C., Smith J. M., Stark G. R., Gardiner K., Mogensen K. E. Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J. 1995 Oct 16;14(20):5100–5108. doi: 10.1002/j.1460-2075.1995.tb00192.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lüscher U., Filgueira L., Juretic A., Zuber M., Lüscher N. J., Heberer M., Spagnoli G. C. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer. 1994 May 15;57(4):612–619. doi: 10.1002/ijc.2910570428. [DOI] [PubMed] [Google Scholar]
- Mahadevappa M., Warrington J. A. A high-density probe array sample preparation method using 10- to 100-fold fewer cells. Nat Biotechnol. 1999 Nov;17(11):1134–1136. doi: 10.1038/15124. [DOI] [PubMed] [Google Scholar]
- Marton M. J., DeRisi J. L., Bennett H. A., Iyer V. R., Meyer M. R., Roberts C. J., Stoughton R., Burchard J., Slade D., Dai H. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med. 1998 Nov;4(11):1293–1301. doi: 10.1038/3282. [DOI] [PubMed] [Google Scholar]
- Noppen C., Lévy F., Burri L., Zajac P., Remmel E., Schaefer C., Lüscher U., Heberer M., Spagnoli G. C. Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2. Int J Cancer. 2000 Jul 15;87(2):241–246. [PubMed] [Google Scholar]
- Pansky A., Hildebrand P., Fasler-Kan E., Baselgia L., Ketterer S., Beglinger C., Heim M. H. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer. 2000 Mar 1;85(5):720–725. doi: 10.1002/(sici)1097-0215(20000301)85:5<720::aid-ijc20>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
- Ralph S. J., Wines B. D., Payne M. J., Grubb D., Hatzinisiriou I., Linnane A. W., Devenish R. J. Resistance of melanoma cell lines to interferons correlates with reduction of IFN-induced tyrosine phosphorylation. Induction of the anti-viral state by IFN is prevented by tyrosine kinase inhibitors. J Immunol. 1995 Mar 1;154(5):2248–2256. [PubMed] [Google Scholar]
- Rasmussen U. B., Wolf C., Mattei M. G., Chenard M. P., Bellocq J. P., Chambon P., Rio M. C., Basset P. Identification of a new interferon-alpha-inducible gene (p27) on human chromosome 14q32 and its expression in breast carcinoma. Cancer Res. 1993 Sep 1;53(17):4096–4101. [PubMed] [Google Scholar]
- Rogge L., Bianchi E., Biffi M., Bono E., Chang S. Y., Alexander H., Santini C., Ferrari G., Sinigaglia L., Seiler M. Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet. 2000 May;25(1):96–101. doi: 10.1038/75671. [DOI] [PubMed] [Google Scholar]
- Spagnoli G. C., Schaefer C., Willimann T. E., Kocher T., Amoroso A., Juretic A., Zuber M., Luscher U., Harder F., Heberer M. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int J Cancer. 1995 Oct 20;64(5):309–315. doi: 10.1002/ijc.2910640505. [DOI] [PubMed] [Google Scholar]
- Tenhunen J., Salminen M., Lundström K., Kiviluoto T., Savolainen R., Ulmanen I. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem. 1994 Aug 1;223(3):1049–1059. doi: 10.1111/j.1432-1033.1994.tb19083.x. [DOI] [PubMed] [Google Scholar]
- Trapani J. A., Dawson M., Apostolidis V. A., Browne K. A. Genomic organization of IFI16, an interferon-inducible gene whose expression is associated with human myeloid cell differentiation: correlation of predicted protein domains with exon organization. Immunogenetics. 1994;40(6):415–424. doi: 10.1007/BF00177824. [DOI] [PubMed] [Google Scholar]
- Vial T., Descotes J. Clinical toxicity of the interferons. Drug Saf. 1994 Feb;10(2):115–150. doi: 10.2165/00002018-199410020-00003. [DOI] [PubMed] [Google Scholar]
- Welsh M., Mares J., Karlsson T., Lavergne C., Bréant B., Claesson-Welsh L. Shb is a ubiquitously expressed Src homology 2 protein. Oncogene. 1994 Jan;9(1):19–27. [PubMed] [Google Scholar]
- Wong L. H., Krauer K. G., Hatzinisiriou I., Estcourt M. J., Hersey P., Tam N. D., Edmondson S., Devenish R. J., Ralph S. J. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem. 1997 Nov 7;272(45):28779–28785. doi: 10.1074/jbc.272.45.28779. [DOI] [PubMed] [Google Scholar]
- de La Salmonière P., Grob J. J., Dreno B., Delaunay M., Chastang C. White blood cell count: a prognostic factor and possible subset indicator of optimal treatment with low-dose adjuvant interferon in primary melanoma. Clin Cancer Res. 2000 Dec;6(12):4713–4718. [PubMed] [Google Scholar]